MODICA, CHIARA
MODICA, CHIARA
ONCOLOGIA
Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody
2016-01-01 Cignetto, Simona; Modica, Chiara; Chiriaco, Cristina; Fontani, Lara; Milla, Paola; Michieli, Paolo; Comoglio, Paolo M.; Vigna, Elisa
Hgf/met axis induces tumor secretion of tenascin-c and promotes stromal rewiring in pancreatic cancer
2021-01-01 Modica C.; Olivero M.; Zuppini F.; Milan M.; Basilico C.; Vigna E.
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
2022-01-01 Martinelli I.; Modica C.; Chiriaco C.; Basilico C.; Hughes J.M.; Corso S.; Giordano S.; Comoglio P.M.; Vigna E.
Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours
2019-01-01 Martin, Valentina; Chiriaco, Cristina; Modica, Chiara; Acquadro, Anna; Cortese, Marco; Galimi, Francesco; Perera, Timothy; Gammaitoni, Loretta; Aglietta, Massimo; Comoglio, Paolo M.; Vigna, Elisa; Sangiolo, Dario
MET/HGF co-targeting in pancreatic cancer: A tool to provide insight into the tumor/stroma crosstalk
2018-01-01 Modica C.; Tortarolo D.; Comoglio P.M.; Basilico C.; Vigna E.
A receptor-antibody hybrid hampering MET-driven metastatic spread
2021-01-01 Modica C.; Basilico C.; Chiriaco C.; Borrelli N.; Comoglio P.M.; Vigna E.
Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy
2018-01-01 Basilico C.; Modica C.; Maione F.; Vigna E.; Comoglio P.M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody | 2016 | Cignetto, Simona; Modica, Chiara; Chiriaco, Cristina; Fontani, Lara; Milla, Paola; Michieli, Paolo; Comoglio, Paolo M.; Vigna, Elisa | |
| Hgf/met axis induces tumor secretion of tenascin-c and promotes stromal rewiring in pancreatic cancer | 2021 | Modica C.; Olivero M.; Zuppini F.; Milan M.; Basilico C.; Vigna E. | |
| hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers | 2022 | Martinelli I.; Modica C.; Chiriaco C.; Basilico C.; Hughes J.M.; Corso S.; Giordano S.; Comoglio P.M.; Vigna E. | |
| Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours | 2019 | Martin, Valentina; Chiriaco, Cristina; Modica, Chiara; Acquadro, Anna; Cortese, Marco; Galimi, Francesco; Perera, Timothy; Gammaitoni, Loretta; Aglietta, Massimo; Comoglio, Paolo M.; Vigna, Elisa; Sangiolo, Dario | |
| MET/HGF co-targeting in pancreatic cancer: A tool to provide insight into the tumor/stroma crosstalk | 2018 | Modica C.; Tortarolo D.; Comoglio P.M.; Basilico C.; Vigna E. | |
| A receptor-antibody hybrid hampering MET-driven metastatic spread | 2021 | Modica C.; Basilico C.; Chiriaco C.; Borrelli N.; Comoglio P.M.; Vigna E. | |
| Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-“decoy” strategy | 2018 | Basilico C.; Modica C.; Maione F.; Vigna E.; Comoglio P.M. |